AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03594812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45º. The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis.
Study NCT03594812 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radiofrequency without power
Description: Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45ºC (Celsius degrees). The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis. In this group, the radiofrequency device was switched off.
Study NCT03169842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pancreatic cyst fluid glucose analysis using a bedside glucometer
Description: Small amount of pancreatic cyst fluid will be analyzed for glucose level using a bedside glucometer from EUS-FNA procedures.
Study NCT03594812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 35 minutes); and cooling (from 35 to 40 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
Study NCT03594812 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic exercise
Description: Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 35 minutes); and cooling (from 35 to 40 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
Study NCT04361305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine
Description: 30 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 8 weeks Tadalafil 5 mg tablets every day for 8 weeks
Study NCT04361305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: 5 mg tablets every day for 8 weeks
Study NCT04361305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 mg tablets every day for 8 weeks
Study NCT04545463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FIBRACEP
Description: A total intake of 7 g/day of FIBRACEP (provided in 6 cookies of 15 g/each) during two months
Study NCT04545463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: INSOLUBLE
Description: A total intake of 7 g/day of wheat bran (provided in 6 cookies of 15 g/each) during two months
Study NCT04545463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SOLUBLE
Description: A total intake of 7 g/day of psyllium plantago (provided in 6 cookies of 15g/each) during two months
Study NCT05194527 — intervention group
Intervention type: OTHER
Intervention: Biomarker validation and VOC profile identification
Description: Validation of a panel of plasma markers for the early diagnosis of acute intestinal ischemia with a panel consists of I-FABP, VIL-1, and SM22. Identification of an acute intestinal ischemia specific VOCs profile and evaluate exhaled breath analysis as a diagnostic tool for intestinal ischemia.
Study NCT06318000 — intervention group
Intervention type: OTHER
Intervention: Balance test, bilateral coordination test, fundamental motor skills test
Description: Functional assessment
Study NCT02612194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib was administered orally at 250mg twice daily
Study NCT02662374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: .02% Chlorohexidine Gluconate
Description: 5ml of the drug in mouthwash form to be swished four times a day
Study NCT02662374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: .02% Chlorohexidine Gluconate
Description: 5ml of the drug in mouthwash form to be swished four times a day
Study NCT02662374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Sodium Bicarbonate
Description: 5ml of the drug in the form of a prepared solution to be swished four times a day
Study NCT02662374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Sodium Bicarbonate
Description: 5ml of the drug in the form of a prepared solution to be swished four times a day
Study NCT02662374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nystatin 10000U/ml
Description: 5ml of the drug in mouthwash form to be swished and swallowed four times a day
Study NCT02662374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin 10000U/ml
Description: 5ml of the drug in mouthwash form to be swished and swallowed four times a day
Study NCT02662374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extra Soft Toothbrush
Description: To be moistened with 0.9% normal Saline and used twice daily to remove dental plaque
Study NCT02662374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supersaturated Calcium Phosphate
Description: 5ml of the solution to be swished four times a day
Study NCT04456114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acid etched brackets
Description: The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
Study NCT04456114 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sandblasted brackets
Description: The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
Study NCT01085149 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Simvastatin
Description: 10 mg simvastatin, slow release in socket of extracted tooth (single application only)
Study NCT01085149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 10 mg simvastatin, slow release in socket of extracted tooth (single application only)
Study NCT00612456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib eye drops formulation
Study NCT01920165 — intervention group
Intervention type: OTHER
Intervention: Smoke-free legislation
Description: The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk
Study NCT02429076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV methylphenidate
Description: IV methylphenidate will be administered to induce emergence from general anesthesia.
Study NCT02429076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: normal saline
Study NCT03001687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral supplementation with vitamin D
Description: Patients allocated to the vitamin D + group receive enteral supplementation with high-dose vitamin D (250.000UI)
Study NCT03001687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood collection 3mL
Description: all patients will have hepcidin levels measured in the first 24 hours after admission and one week after
Study NCT03001687 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: blood collection 3mL
Description: all patients will have hepcidin levels measured in the first 24 hours after admission and one week after
Study NCT04977219 — intervention group
Intervention type: BEHAVIORAL
Intervention: Prism Adaptation Training
Description: Therapists administering PAT followed the protocol developed by the Kessler Foundation (2014).PAT sessions lasted approximately 30 minutes during which patients with left sided neglect don 20 diopter prism goggles deviating their visual field to the right while aiming their finger at a series of visual targets.
Study NCT01537822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellator
Description: Morcellation will be performed with the HM (TRUCLEAR, Smith \& Nephew, Andover, USA). The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy. The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source. The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.
Study NCT01537822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resectoscope
Description: Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic. Normal saline is used for distension and irrigation of the uterine cavity. Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
Study NCT02429076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhaled anesthetic
Study NCT02429076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: IV anesthetic
Study NCT04424589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: Myofascial release or induction (IMF) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. The experimental group will receive 1 examination session and 6 myofascial induction sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for spinal at the level of the lumbar square, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks.
Study NCT04424589 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham therapy
Description: The control group will receive 1 examination session and 6 simulated myofascial induction sessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial induction, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
Study NCT00469391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GI Sleeve Implantable weight loss device (EndoBarrier)
Description: device for weight loss
Study NCT03326856 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation
Study NCT00469391 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Weight loss
Study NCT00592644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulse Dye laser (PDL)
Description: one-time PDL, in 10 subjects
Study NCT00592644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser or other traditional surgeries
Description: once-time CO2 laser or other conventional surgeries, in other 10 subjects
Study NCT04477018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron bis-glycinate chelate and vitamin C
Description: 28 mg iron; 240 mg vitamin C
Study NCT04477018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron bis-glycinate chelate
Description: 28 mg iron only
Study NCT04477018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT03579862 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Study NCT01183299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary salt intake
Study NCT01183299 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary salt intake
Study NCT03550976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The low-GI diet and muscle training
Description: During the 12-28 weeks of pregnancy, the pregnant women received low-GI diet and exercise intervention.Every two weeks, the pregnant women were followed up to assess the dietary situation and analyze the body composition results.Collect birth outcomes
Study NCT00956046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
Study NCT00956046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
Study NCT00524017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: given IV
Study NCT02898298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Emotion Regulation Training
Description: Participants will receive a 3-session psycho-educative training on emotion regulation.
Study NCT00956046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21
Study NCT03163290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posterolateral Hip Complex Exercises
Description: The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: abduction exercise, Clam exercise and external rotation exercise
Study NCT03163290 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anteromedial Hip Complex Exercises
Description: The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise.
Study NCT01265628 — intervention group
Intervention type: PROCEDURE
Intervention: perimetry
Description: automated static perimetry with adapted GATE strategy
Study NCT04191928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban is an orally administered highly selective factor Xa inhibitor, belonging to the class of direct-acting oral anticoagulants (DOAC) along with rivaroxoban and edoxaban. Factor Xa is an essential mediator of the clotting pathway in humans. Apixaban is currently approved by the FDA for treatment of VTE, prophylaxis of DVT in patients undergoing knee and hip replacement surgeries and for reducing the risk of embolic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Study NCT02288416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo video-based intervention
Study NCT02288416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02288416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02288416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02288416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02288416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Study NCT02898298 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Emotion Regulation Training
Description: Participants will receive a 3-session psycho-educative training on emotion regulation.
Study NCT00426101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal therapy
Description: If at 2 wks there are progressive neurological symptoms or if an abnormal CSF (cell count and protein) has not improved, then give 4 wkly intrathecal inj. Be aware that some pat may have increased intracranial pressure.~Methotrexate: \<1 yr 6 mg, 1-2 yrs 8 mg, 2-3 yrs 10 mg, >3 yrs 12 mg. Prednisolone: \<1 yr 4 mg, 1-2 yrs 6 mg, 2-3 yrs 8 mg, >3 yrs 10 mg.
Study NCT00426101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Description: The SCT procedure is up to the treating physician. However, a suggested regimen is provided.
Study NCT03901976 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: bed exit detection
Description: bed exit detection to avoid patients fall
Study NCT01184443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Dosing regimen is in keeping with clinical practice. Patients will typically start oral olanzapine at 2.5mg (rarely 1.25mg) daily for 1 to 2 weeks, and if tolerated and clinically indicated, are increased to 5.0mg daily. The majority of patients will remain on a maintenance dose of 5.0mg, but more agitated patients may take 7.5mg (rarely 10.0mg) daily. Patients will be tapered off as they approach/attain their ideal body weight.
Study NCT01331850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000 mg or 1200 mg daily oral doses for 24 weeks
Study NCT00537381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
Study NCT00694759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: 30 mg for 2 weeks, then 45 mg daily
Study NCT00694759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 500mg twice daily for 1 week, then 1000 mg twice daily
Study NCT00694759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsule twice daily
Study NCT05486221 — intervention group
Intervention type: OTHER
Intervention: Extensive cardiologic work-up
Description: Specific 3D and 2D echocardiography measuring left ventricule and left atrial dimensions as well as longitudinal strain. 30 day prolonged ECG monitoring.
Study NCT03403959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light therapy
Description: 6 weeks morning treatment with bright light therapy in own home.
Study NCT01066754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Fexofenadine Hydrochloride 180 mg Tablets
Study NCT01066754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine Hydrochloride 180 mg Tablets
Study NCT03559140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Applied saline solution at 2.5 oC (Cryotherapy group)
Description: Patients assigned to this group will receive a final irrigation (application of cryotherapy) with 5 mL cold (8oC) 17% EDTA followed with 20 mL cold (8oC) sterile saline solution delivered to the WL using a cold (8oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
Study NCT03559140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Applied saline solution at 8oC (Cryotherapy )
Description: Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
Study NCT03559140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Applied saline solution at room temperature (No cryotherapy)
Description: Patients assigned to this control group were treated identically to the experimental groups, except that they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
Study NCT00725218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline 5 ml injection 10 min prior to propofol administration.
Study NCT00725218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen Axetil
Description: Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
Study NCT00731770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Advair 250
Description: 1 puff bid inhaled
Study NCT00731770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- matched
Description: 1 puff bid inhaled
Study NCT00731770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo 1 puff bid inhaled
Study NCT00731770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair 250 - matched
Description: i puff bid inhaled